Lentivirus-mediated gene therapy for Fabry disease

Nature Communications

12, 1178

DOI: 10.1038/s41467-021-21371-5

Citation Report

#	Article	IF	Citations
1	Andersonâ€“Fabry Disease: From Endothelial Dysfunction to Emerging Therapies. Advances in Pharmacological and Pharmaceutical Sciences, 2021, 2021, 1-9.	0.7	4
2	Fabry Cardiomyopathy: Current Practice and Future Directions. Cells, 2021, 10, 1532.	1.8	9
3	Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Molecular Genetics and Metabolism, 2021, 134, 117-131.	0.5	13
4	Fabry Cardiomyopathy: Current Treatment and Future Options. Journal of Clinical Medicine, 2021, 10, 3026.	1.0	8
7	Phenocopies of sarcomere gene mediated hypertrophic cardiomyopathy in children. Progress in Pediatric Cardiology, 2021, 62, 101419.	0.2	0
8	Using insights from genomics to increase possibilities for treatment of genetic diseases. , 2022, , 309-358.		1
9	Therapeutic Approaches in Lysosomal Storage Diseases. Biomolecules, 2021, 11, 1775.	1.8	24
10	Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases. Molecular Therapy - Methods and Clinical Development, 2022, 24, 71-87.	1.8	5
11	Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease. Cell Transplantation, 2021, 30, 096368972110602.	1.2	3
12	Gene Therapy Developments for Pompe Disease. Biomedicines, 2022, 10, 302.	1.4	19
14	Lysosphingolipid urine screening test using mass spectrometry for theÂearly detection of lysosomal storage disorders. Bioanalysis, 2022, 14, 289-306.	0.6	1
16	Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates. Nature Chemical Biology, 2022, 18, 332-341.	3.9	11
17	Autologous, lentivirusâ€modified, Tâ€rapa cell â€œmicropharmaciesâ€•for lysosomal storage disorders. EMBO Molecular Medicine, 2022, 14, e14297.	3.3	5
18	A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nature Communications, 2022, 13, 1315.	5.8	61
19	The Chromosomes and the Kidney. Physician Assistant Clinics, 2022, 7, 367-375.	0.1	0
20	Gene therapy for kidney disease: targeting cystinuria. Current Opinion in Nephrology and Hypertension, 2022, 31, 175-179.	1.0	3
21	Haematopoietic stem cell gene therapy in inborn errors of metabolism. British Journal of Haematology, 2022, 198, 227-243.	1.2	5
22	High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing. Molecular Therapy, 2022, 30, 3209-3225.	3.7	4

#	Article	IF	Citations
23	Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review. Current Neuropharmacology, 2023, 21, 440-456.	1.4	8
24	Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease. Frontiers in Pediatrics, 2022, 10, .	0.9	6
25	Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment. Journal of Personalized Medicine, 2022, 12, 922.	1.1	0
26	Gene Therapy for Pediatric Neurologic Disease. Hematology/Oncology Clinics of North America, 2022, , .	0.9	0
27	Therapeutic Strategies For Tay-Sachs Disease. Frontiers in Pharmacology, 0, 13, .	1.6	7
29	Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders. Advanced Drug Delivery Reviews, 2022, 188, 114465.	6.6	17
30	Emerging cellular themes in leukodystrophies. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
31	Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles. Scientific Reports, 2022, 12, .	1.6	8
32	Cardiac involvement in Fabry disease - A non-invasive assessment and the role of specific therapies. Molecular Genetics and Metabolism, 2022, 137, 179-186.	0.5	0
33	Fabry disease: Mechanism and therapeutics strategies. Frontiers in Pharmacology, 0, 13, .	1.6	14
34	Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease. Molecular Therapy - Methods and Clinical Development, 2022, 27, 464-487.	1.8	4
35	Genetics of Kidney Disease: The Unexpected Role of Rare Disorders. Annual Review of Medicine, 2023, 74, 353-367.	5.0	3
36	Gene therapy for lysosomal storage diseases: Current clinical trial prospects. Frontiers in Genetics, 0, 14, .	1.1	10
37	Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Molecular Therapy - Methods and Clinical Development, 2023, 28, 262-271.	1.8	4
38	Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook. Therapeutics and Clinical Risk Management, 0, Volume 19, 115-132.	0.9	10
39	Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions. Biomolecules, 2023, 13, 274.	1.8	2
40	Cardiac MRI in Fabry disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
41	Gene Therapy of Sphingolipid Metabolic Disorders. International Journal of Molecular Sciences, 2023, 24, 3627.	1.8	6

#	Article	IF	Citations
42	Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals, 2023, 16, 320.	1.7	5
43	Ex vivo gene therapy for lysosomal storage disorders: future perspectives. Expert Opinion on Biological Therapy, 2023, 23, 353-364.	1.4	1
44	Optimizing human Î±-galactosidase for treatment of Fabry disease. Scientific Reports, 2023, 13, .	1.6	2
45	Cell and gene therapy for kidney disease. Nature Reviews Nephrology, 2023, 19, 451-462.	4.1	7
57	Outcomes and management of kidney transplant recipients with Fabry disease: a review. Journal of Nephrology, 0, , .	0.9	0